Parkin-deficient Mice Exhibit Nigrostriatal Deficits but Not Loss of Dopaminergic Neurons
Open accessThe DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Abstract
Loss-of-function mutations in parkin are the major cause of early-onset familial Parkinson's disease. To investigate the pathogenic mechanism by which loss of parkin function causes Parkinson's disease, we generated a mouse model bearing a germline disruption in parkin. Parkin-/- mice are viable and exhibit grossly normal brain morphology. Quantitative in vivo microdialysis revealed an increase in extracellular dopamine concentration in the striatum of parkin-/- mice. Intracellular recordings of medium-sized striatal spiny neurons showed that greater currents are required to induce synaptic responses, suggesting a reduction in synaptic excitability in the absence of parkin. Furthermore, parkin-/- mice exhibit deficits in behavioral paradigms sensitive to dysfunction of the nigrostriatal pathway. The number of dopaminergic neurons in the substantia nigra of parkin-/- mice, however, is normal up to the age of 24 months, in contrast to the substantial loss of nigral neurons characteristic of Parkinson's disease. Steady-state levels of CDCrel-1, synphilin-1, and alpha-synuclein, which were identified previously as substrates of the E3 ubiquitin ligase activity of parkin, are unaltered in parkin-/- brains. Together these findings provide the first evidence for a novel role of parkin in dopamine regulation and nigrostriatal function, and a non-essential role of parkin in the survival of nigral neurons in mice.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Importantly, parkin-deficient mice and mice expressing a dominant negative form of Nrdp1 are not reported to have significant neurodegenerative disease171819.”
From Clec16a is Critical for Autolysosome Function and Purkinje Cell Survival (2016) · cites this paper as [18]
In the citing paper
“The lack of reported neurodegeneration in parkin-deficient and Nrdp1 mutant mice171819 makes it unlikely that this interaction explains our finding of neurodegeneration in Clec16a mutant mice.”
From Clec16a is Critical for Autolysosome Function and Purkinje Cell Survival (2016) · cites this paper as [18]
In the citing paper
“Although PINK1 (McWilliams et al, 2018) and PRKN (Goldberg et al, 2003; Perez & Palmiter, 2005) deficiency do not elicit major defects under baseline conditions, defective striatal neural plasticity is observed in prkn− / − mice (Kitada et al, 2009).”
From Autophagy in major human diseases (2021) · cites this paper as Goldberg et al, 2003
Citations
Cites
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227
Mutations in the DJ-1 Gene Associated with Autosomal Recessive Early-Onset Parkinsonism
Bonifati, V., Rizzu, P., van Baren, M. J., Schaap, O., Breedveld, G. J., Krieger, E., Dekker, M. C. J., Squitieri, F., Ibanez, P., Joosse, M., et al. (2003) · Science · doi:10.1126/science.1077209 · Cited by 2,778
The unbiased estimation of number and sizes of arbitrary particles using the disector
Sterio, D. C. (1984) · Journal of Microscopy · doi:10.1111/j.1365-2818.1984.tb02501.x · Cited by 2,519
Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase
Shimura, H., Hattori, N., Kubo, S.-I., Mizuno, Y., Asakawa, S., Minoshima, S., Shimizu, N., Iwai, K., Chiba, T., Tanaka, K., et al. (2000) · Nature Genetics · doi:10.1038/77060 · Cited by 2,024
Masliah, E., Rockenstein, E., Veinbergs, I., Mallory, M., Hashimoto, M., Takeda, A., Sagara, Y., Sisk, A., & Mucke, L. (2000) · Science · doi:10.1126/science.287.5456.1265 · Cited by 1,765
Dunham, N. W., & Miya, T. S. (1957) · Journal of the American Pharmaceutical Association (Scientific ed.) · doi:10.1002/jps.3030460322 · Cited by 1,716
Association between Early-Onset Parkinson's Disease and Mutations in the Parkin Gene
Lücking, C. B., Dürr, A., Bonifati, V., Vaughan, J., De Michele, G., Gasser, T., Harhangi, B. S., Meco, G., Denèfle, P., Wood, N. W., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005253422103 · Cited by 1,433
Schallert, T., Fleming, S. M., Leasure, J. L., Tillerson, J. L., & Bland, S. T. (2000) · Neuropharmacology · doi:10.1016/s0028-3908(00)00005-8 · Cited by 1,354
Self-citationNeuronal α-Synucleinopathy with Severe Movement Disorder in Mice Expressing A53T Human α-Synuclein
Giasson, B. I., Duda, J. E., Quinn, S. M., Zhang, B., Trojanowski, J. Q., & Lee, V. M.-Y. (2002) · Neuron · doi:10.1016/s0896-6273(02)00682-7 · Cited by 1,266
Research works printed but not linked: 4
- Tanner, 1990, Neurology, 40, 17
- Parsons, 1994, Crit. Rev. Neurobiol., 8, 189
- Walsh, 1992, J. Pharmacol. Exp. Ther., 263, 617
- Schallert, 1988, Vol. 515, 108
Cited by
The Roles of PINK1, Parkin, and Mitochondrial Fidelity in Parkinson’s Disease
Pickrell, A. M., & Youle, R. J. (2015) · Neuron · doi:10.1016/j.neuron.2014.12.007 · Cited by 2,310
“The first two Parkin-KO mouse models lacked exon 3 and exhibited only mild phenotypes, such as the disruption of fine motor skills and slight abnormalities in dopamine metabolism and release, but, disappointingly, no dopaminergic neuron loss (Goldberg et al., 2003; Itier et al., 2003).”
BackgroundPINK1-dependent recruitment of Parkin to mitochondria in mitophagy
Vives-Bauza, C., Zhou, C., Huang, Y., Cui, M., de Vries, R. L. A., Kim, J., May, J., Tocilescu, M. A., Liu, W., Ko, H. S., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0911187107 · Cited by 1,616
“The interplay between PINK1 and Parkin in mitochondrial functioning also may modulate the trafficking of mitochondria in dendrites, perhaps accounting for the synaptic dysfunction that is observed in PINK1- or Parkin-knockout mice (22, 23).”
BackgroundAutophagy in major human diseases
Klionsky, D. J., Petroni, G., Amaravadi, R. K., Baehrecke, E. H., Ballabio, A., Boya, P., Bravo‐San Pedro, J. M., Cadwell, K., Cecconi, F., Choi, A. M. K., et al. (2021) · The EMBO Journal · doi:10.15252/embj.2021108863 · Cited by 1,585
RETRACTED ARTICLE: Parkin and PINK1 mitigate STING-induced inflammation
Sliter, D. A., Martinez, J., Hao, L., Chen, X., Sun, N., Fischer, T. D., Burman, J. L., Li, Y., Zhang, Z., Narendra, D. P., et al. (2018) · Nature · doi:10.1038/s41586-018-0448-9 · Cited by 1,287
RetractedMOLECULAR PATHOPHYSIOLOGY OF PARKINSON'S DISEASE
Moore, D. J., West, A. B., Dawson, V. L., & Dawson, T. M. (2005) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.28.061604.135718 · Cited by 1,280
“Two of the knockouts show subtle behavioral deficits, mild alterations of dopaminergic and glutamatergic neurotransmission, and abnormalities in dopamine metabolism (Goldberg et al. 2003, Itier et al. 2003).”
BackgroundPINK1 and Parkin Target Miro for Phosphorylation and Degradation to Arrest Mitochondrial Motility
Wang, X., Winter, D., Ashrafi, G., Schlehe, J., Wong, Y. L., Selkoe, D., Rice, S., Steen, J., LaVoie, M. J., & Schwarz, T. L. (2011) · Cell · doi:10.1016/j.cell.2011.10.018 · Cited by 1,171
Autophagy and Neurodegeneration: Pathogenic Mechanisms and Therapeutic Opportunities
Menzies, F. M., Fleming, A., Caricasole, A., Bento, C. F., Andrews, S. P., Ashkenazi, A., Füllgrabe, J., Jackson, A., Jimenez Sanchez, M., Karabiyik, C., et al. (2017) · Neuron · doi:10.1016/j.neuron.2017.01.022 · Cited by 1,134
“Although no gross behavioural changes were found in mice where Parkin was deleted (Goldberg et al., 2003; Itier et al., 2003; Perez and Palmiter, 2005; Von Coelln et al., 2004), the activity of striatal neuron mitochondria was impaired (Palacino et al., 2004).”
Mitochondrial Dysfunction and Oxidative Damage in parkin-deficient Mice
Palacino, J. J., Sagi, D., Goldberg, M. S., Krauss, S., Motz, C., Wacker, M., Klose, J., & Shen, J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m401135200 · Cited by 995
Self-citationThe Ubiquitin Proteasome System in Neurodegenerative Diseases
Ciechanover, A., & Brundin, P. (2003) · Neuron · doi:10.1016/s0896-6273(03)00606-8 · Cited by 982
PARIS (ZNF746) Repression of PGC-1α Contributes to Neurodegeneration in Parkinson's Disease
Shin, J.-H., Ko, H. S., Kang, H., Lee, Y., Lee, Y.-I., Pletinkova, O., Troconso, J. C., Dawson, V. L., & Dawson, T. M. (2011) · Cell · doi:10.1016/j.cell.2011.02.010 · Cited by 953
“Dopaminergic Degeneration in Conditional Parkin KO Mice Germline deletion of parkin using a variety of approaches created parkin KO mice with minimal phenotypes and no loss of DA neurons (Goldberg et al., 2003; Von Coelln et al., 2004).”
Autophagy maintains the metabolism and function of young and old stem cells
Ho, T. T., Warr, M. R., Adelman, E. R., Lansinger, O. M., Flach, J., Verovskaya, E. V., Figueroa, M. E., & Passegué, E. (2017) · Nature · doi:10.1038/nature21388 · Cited by 896
“Further characterization of Park2−/− mice also revealed no similarities to the phenotypes of Atg12cKO mice, and normal function of Park2−/− HSCs in transplantation experiments (Extended Data Fig.”
BackgroundInfluentialMitochondria in the aetiology and pathogenesis of Parkinson's disease
Schapira, A. H. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70327-7 · Cited by 883
Mitochondrial DNA in inflammation and immunity
Riley, J. S., & Tait, S. W. (2020) · EMBO reports · doi:10.15252/embr.201949799 · Cited by 865
Expanding insights of mitochondrial dysfunction in Parkinson's disease
Abou-Sleiman, P. M., Muqit, M. M. K., & Wood, N. W. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1868 · Cited by 869
“Intriguingly, parkin deficiency in these mice did not cause dopaminergic degeneration, which is also observed in exon 2 and other exon 3 deletion model”
BackgroundCell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases
Selkoe, D. J. (2004) · Nature Cell Biology · doi:10.1038/ncb1104-1054 · Cited by 863
“Several substrates for the ubiquitin-ligase function of Parkin have been suggested, but there is no agreement as to which of these are bona fide substrates in vivo , as homozygous deletion of Parkin in mice does not seem to elevate brain levels of these proteins, although it also does not produce dopaminergic neuronal…”
BackgroundA new pathway for mitochondrial quality control: Mitochondrial-derived vesicles
Sugiura, A., McLelland, G., Fon, E. A., & McBride, H. M. (2014) · The EMBO Journal · doi:10.15252/embj.201488104 · Cited by 862
“However, the loss of PINK1 or Parkin in mice leads to very mild phenotypes and a notable absence of neurodegeneration (Goldberg et al, 2003; Kitada et al, 2009).”
BackgroundJiang, P., & Mizushima, N. (2014) · Cell Research · doi:10.1038/cr.2013.161 · Cited by 775
Divergent roles of ALS-linked proteins FUS/TLS and TDP-43 intersect in processing long pre-mRNAs
Lagier-Tourenne, C., Polymenidou, M., Hutt, K. R., Vu, A. Q., Baughn, M., Huelga, S. C., Clutario, K. M., Ling, S.-C., Liang, T. Y., Mazur, C., et al. (2012) · Nature Neuroscience · doi:10.1038/nn.3230 · Cited by 738
Dopamine covalently modifies and functionally inactivates parkin
LaVoie, M. J., Ostaszewski, B. L., Weihofen, A., Schlossmacher, M. G., & Selkoe, D. J. (2005) · Nature Medicine · doi:10.1038/nm1314 · Cited by 722
“2b ), whose immunospecificity has been established in independent report”
BackgroundCellular mitophagy: Mechanism, roles in diseases and small molecule pharmacological regulation
Lu, Y., Li, Z., Zhang, S., Zhang, T., Liu, Y., & Zhang, L. (2023) · Theranostics · doi:10.7150/thno.79876 · Cited by 685
“According to previous research, Parkin KO animals had abnormal nigrostriatal pathway function, reduced synaptic excitability in spiny neurons, and an increase in extracellular dopamine concentration in the striatum [62].”
ResultKim, R. H., Smith, P. D., Aleyasin, H., Hayley, S., Mount, M. P., Pownall, S., Wakeham, A., You-Ten, A. J., Kalia, S. K., Horne, P., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501282102 · Cited by 701
Mitochondrial dysfunction in Parkinson's disease
Winklhofer, K. F., & Haass, C. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.08.013 · Cited by 688
“an increase of extracellular striatal dopamine occurred in some parkin knockout mice (Δexon3; [208,209].”
BackgroundTHE BIOCHEMISTRY OF PARKINSON'S DISEASE
Cookson, M. R. (2005) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.74.082803.133400 · Cited by 664
A rotarod test for evaluation of motor skill learning
Shiotsuki, H., Yoshimi, K., Shimo, Y., Funayama, M., Takamatsu, Y., Ikeda, K., Takahashi, R., Kitazawa, S., & Hattori, N. (2010) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2010.03.026 · Cited by 627
“Several studies have failed to detect impairment n gait performance of Parkin-deficient mice (Goldberg et al., 2003; on Coelln et al., 2004; Perez and Palmiter, 2005; Sato et al., 2006), ut impairment of motor skill learning was evident in our modified otarod test.”
BackgroundBharali, D. J., Klejbor, I., Stachowiak, E. K., Dutta, P., Roy, I., Kaur, N., Bergey, E. J., Prasad, P. N., & Stachowiak, M. K. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504926102 · Cited by 622
Mitochondria in health, disease, and aging
Harrington, J. S., Ryter, S. W., Plataki, M., Price, D. R., & Choi, A. M. K. (2023) · Physiological Reviews · doi:10.1152/physrev.00058.2021 · Cited by 602
What Genetics Tells us About the Causes and Mechanisms of Parkinson's Disease
Corti, O., Lesage, S., & Brice, A. (2011) · Physiological Reviews · doi:10.1152/physrev.00022.2010 · Cited by 611
Mitophagy-dependent necroptosis contributes to the pathogenesis of COPD
Mizumura, K., Cloonan, S. M., Nakahira, K., Bhashyam, A. R., Cervo, M., Kitada, T., Glass, K., Owen, C. A., Mahmood, A., Washko, G. R., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci74985 · Cited by 611
The ubiquitin ligase parkin mediates resistance to intracellular pathogens
Manzanillo, P. S., Ayres, J. S., Watson, R. O., Collins, A. C., Souza, G., Rae, C. S., Schneider, D. S., Nakamura, K., Shiloh, M. U., & Cox, J. S. (2013) · Nature · doi:10.1038/nature12566 · Cited by 588
Lim, K. L., Chew, K. C. M., Tan, J. M. M., Wang, C., Chung, K. K. K., Zhang, Y., Tanaka, Y., Smith, W., Engelender, S., Ross, C. A., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.4474-04.2005 · Cited by 503
“Consistent with the notion that parkin ubiquitinates synphilin-1 via non-K48-linked ubiquitin chains is the lack of differences in the steady-state levels of synphilin-1 in parkindeficient mice compared with their wild-type littermates (Goldberg et al., 2003; Von Coelln et al., 2004).”
BackgroundThe role of PINK1–Parkin in mitochondrial quality control
Narendra, D. P., & Youle, R. J. (2024) · Nature Cell Biology · doi:10.1038/s41556-024-01513-9 · Cited by 520
“…of rat DA neurons 124 , which may account for the selective vulnerability of these cells to bioenergetic deficits in humans compared to other species and the failure of genetic mouse models, including Pink1 KO 125 and Parkin KO mice 126 , to recapitulate the DA neuronal loss observed in humans.”
Impaired dopamine release and synaptic plasticity in the striatum of PINK1 -deficient mice
Kitada, T., Pisani, A., Porter, D. R., Yamaguchi, H., Tscherter, A., Martella, G., Bonsi, P., Zhang, C., Pothos, E. N., & Shen, J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702717104 · Cited by 540
Self-citationGoldberg, M. S., Pisani, A., Haburcak, M., Vortherms, T. A., Kitada, T., Costa, C., Tong, Y., Martella, G., Tscherter, A., Martins, A., et al. (2005) · Neuron · doi:10.1016/j.neuron.2005.01.041 · Cited by 538
“DA Neuron Count, Striatal Dopamine Measurement, Radioligand Binding Assay, and Real-Time RT-PCR DA neuron count and striatal DA measurements were done exactly as previously described (Goldberg et al., 2003).”
BackgroundMethodInfluentialSelf-citationHoshino, A., Mita, Y., Okawa, Y., Ariyoshi, M., Iwai-Kanai, E., Ueyama, T., Ikeda, K., Ogata, T., & Matoba, S. (2013) · Nature Communications · doi:10.1038/ncomms3308 · Cited by 536
The genetics of Parkinson disease
Deng, H., Wang, P., & Jankovic, J. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2017.12.007 · Cited by 530
“Prkn-/- mice also exhibit mitochondrial dysfunction, striatonigral deficits but no loss of DA neurons (Goldberg et al., 2003).”
BackgroundMaiti, P., Manna, J., & Dunbar, G. L. (2017) · Translational Neurodegeneration · doi:10.1186/s40035-017-0099-z · Cited by 525
“To prove the link between the UPS and PD, researchers also developed genetic models of PD, such as parkin-mutated mice, although this mouse model lacks overt signs of parkinsonism [108].”
BackgroundMurakawa, T., Yamaguchi, O., Hashimoto, A., Hikoso, S., Takeda, T., Oka, T., Yasui, H., Ueda, H., Akazawa, Y., Nakayama, H., et al. (2015) · Nature Communications · doi:10.1038/ncomms8527 · Cited by 517
“The Parkin-deficient mice have only modest phenotypes 14, 29 and Parkin is not expressed in all cell-types, suggesting the presence of alternate pathways of mitophagy.”
Ashrafi, G., Schlehe, J. S., LaVoie, M. J., & Schwarz, T. L. (2014) · Journal of Cell Biology · doi:10.1083/jcb.201401070 · Cited by 502
“129S4-Park2 tm1Shn (exon 3 deletion), and their control mice have been previously described (Goldberg et al., 2003).”
Targeting Proteins for Destruction by the Ubiquitin System: Implications for Human Pathobiology
Schwartz, A. L., & Ciechanover, A. (2009) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.051208.165340 · Cited by 492
PINK1/PARKIN signalling in neurodegeneration and neuroinflammation
Quinn, P. M. J., Moreira, P. I., Ambrósio, A. F., & Alves, C. H. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-01062-w · Cited by 481
“Parkin KO mice have an increase in extracellular dopamine concentration in the striatum, there is reduction in synaptic excitability in spiny neurons and dysfunction of the nigrostriatal pathway [131].”
BackgroundParkinson’s disease: animal models and dopaminergic cell vulnerability
Blesa, J., & Przedborski, S. (2014) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2014.00155 · Cited by 480
“Some of these KO mice exhibit slightly impaired DA release (Itier et al., 2003; Kitada et al., 2009a) and reduced norepinephrine levels in the olfactory bulb and spinal cord with an abnormal nigrostriatal region but without loss of SNc neurons (Goldberg et al., 2003; Von Coelln et al., 2004).”
BackgroundEarly and Progressive Sensorimotor Anomalies in Mice Overexpressing Wild-Type Human α-Synuclein
Fleming, S. M., Salcedo, J., Fernagut, P.-O., Rockenstein, E., Masliah, E., Levine, M. S., & Chesselet, M.-F. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.3080-04.2004 · Cited by 474
Self-citationParkin-deficient mice are not a robust model of parkinsonism
Perez, F. A., & Palmiter, R. D. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409598102 · Cited by 477
Kubli, D. A., Zhang, X., Lee, Y., Hanna, R. A., Quinsay, M. N., Nguyen, C. K., Jimenez, R., Petrosyan, S., Murphy, A. N., & Gustafsson, Å. B. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.411363 · Cited by 476
“129S4-Park2/J, stock number 006582) and have been described previously (15).”
BackgroundShults, C. W. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509567103 · Cited by 476
Mitochondrial dynamics in neurodegeneration
Itoh, K., Nakamura, K., Iijima, M., & Sesaki, H. (2013) · Trends in Cell Biology · doi:10.1016/j.tcb.2012.10.006 · Cited by 464
The pathogenesis of cell death in Parkinson's disease
Jenner, P., & Olanow, C. W. (2006) · Neurology · doi:10.1212/wnl.66.10_suppl_4.s24 · Cited by 446
Pesah, Y., Pham, T., Burgess, H., Middlebrooks, B., Verstreken, P., Zhou, Y., Harding, M., Bellen, H., & Mardon, G. (2004) · Development · doi:10.1242/dev.01095 · Cited by 443
“However, increased extracellular DA concentration, abnormal neurophysiology and motor and cognitive behavioral deficits are observed in PARK2 mutant mice (Goldberg et al., 2003; Itier et al., 2003).”
Mhyre, T. R., Boyd, J. T., Hamill, R. W., & Maguire-Zeiss, K. A. (2012) · Subcellular Biochemistry · doi:10.1007/978-94-007-5416-4_16 · Cited by 423
“Loss-of-function of parkin in the mouse has also been shown to induce nigrostriatal dysfunction (Goldberg et al. 2003; Itier et al. 2003; RodriguezNavarro et al. 2007; Stichel et al. 2007; Kitada et al. 2009).”
BackgroundMitochondria and Neuroplasticity
Cheng, A., Hou, Y., & Mattson, M. P. (2010) · ASN Neuro · doi:10.1042/an20100019 · Cited by 430
“Studies of nigrostriatal neurons in Parkin-null mice suggest that Parkin is a negative regulator of dopamine release (Goldberg et al., 2003).”
BackgroundParkin, a p53 target gene, mediates the role of p53 in glucose metabolism and the Warburg effect
Zhang, C., Lin, M., Wu, R., Wang, X., Yang, B., Levine, A. J., Hu, W., & Feng, Z. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1113884108 · Cited by 431
“To study the impact of Parkin deficiency upon tumorigenesis, 2-mo-old Parkin and Parkin C57BL6/J malemice (28) were subjected to a single dose of 4-Gy IR.”
MethodInfluentialLee, Y., Lee, H.-Y., Hanna, R. A., & Gustafsson, Å. B. (2011) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00368.2011 · Cited by 397
“Park2 knockout mice were obtained from Jackson Laboratories and have been described previously (9).”
MethodParkin, PINK1, and DJ-1 form a ubiquitin E3 ligase complex promoting unfolded protein degradation
Xiong, H., Wang, D., Chen, L., Choo, Y. S., Ma, H., Tang, C., Xia, K., Jiang, W., Ronai, Z., Zhuang, X., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37617 · Cited by 392
Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice
Iancu, R., Mohapel, P., Brundin, P., & Paul, G. (2005) · Behavioural Brain Research · doi:10.1016/j.bbr.2005.02.023 · Cited by 376
“Although MPTP is a valuable model of PD in mice and non-human primates, it is limited for several reasons: MPTP injection causes a bilateral parkinson syndrome, thereby ruling out all behavioral tests based on a side bias.”
BackgroundImaizumi, Y., Okada, Y., Akamatsu, W., Koike, M., Kuzumaki, N., Hayakawa, H., Nihira, T., Kobayashi, T., Ohyama, M., Sato, S., et al. (2012) · Molecular Brain · doi:10.1186/1756-6606-5-35 · Cited by 380
“; licensee BioMed Centr Commons Attribution License (http://creativec reproduction in any medium, provided the or not replicate all of the pathogenic changes seen in human PARK2 neurons; thus, these models do not fully account for the molecular mechanisms of PD [6-9].”
BackgroundUbiquitin signalling in neurodegeneration: mechanisms and therapeutic opportunities
Schmidt, M. F., Gan, Z. Y., Komander, D., & Dewson, G. (2021) · Cell Death & Differentiation · doi:10.1038/s41418-020-00706-7 · Cited by 368
Martinat, C., Shendelman, S., Jonason, A., Leete, T., Beal, M. F., Yang, L., Floss, T., & Abeliovich, A. (2004) · PLoS Biology · doi:10.1371/journal.pbio.0020327 · Cited by 364
“Furthermore, pathological analyses of PD substantia nigra have correlated cellular oxidative stress and altered proteasomal function with PD. Homozygous mutations in DJ-1 were recently described in two families with autosomal recessive Parkinsonism, one of which is a large deletion that is likely to lead to loss of fu…”
BackgroundInfluentialFallon, L., Bélanger, C. M. L., Corera, A. T., Kontogiannea, M., Regan-Klapisz, E., Moreau, F., Voortman, J., Haber, M., Rouleau, G., Thorarinsdottir, T., et al. (2006) · Nature Cell Biology · doi:10.1038/ncb1441 · Cited by 317
“Although several parkin substrates have been identified, reports of their accumulation in the brains of parkin knockout mice have been conflictin”
BackgroundAutophagy in Parkinson's Disease
Hou, X., Watzlawik, J. O., Fiesel, F. C., & Springer, W. (2020) · Journal of Molecular Biology · doi:10.1016/j.jmb.2020.01.037 · Cited by 352
“Yet, PRKN deletion still resulted in reduced striatal synaptic excitability and plasticity, impaired dopamine release, and nigrostriatal deficits [125, 127].”
BackgroundLoss of locus coeruleus neurons and reduced startle in parkin null mice
von Coelln, R., Thomas, B., Savitt, J. M., Lim, K. L., Sasaki, M., Hess, E. J., Dawson, V. L., & Dawson, T. M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401297101 · Cited by 347
The two-century journey of Parkinson disease research
Przedborski, S. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2017.25 · Cited by 345
Li, X., Patel, J. C., Wang, J., Avshalumov, M. V., Nicholson, C., Buxbaum, J. D., Elder, G. A., Rice, M. E., & Yue, Z. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.5604-09.2010 · Cited by 341
“Moreover, other genetic mouse models for PD also exhibit aberrant DA transmission in the absence of nigrostriatal degeneration (Abeliovich et al., 2000; Goldberg et al., 2003; Chen et al., 2005; Kitada et al., 2007; Zhou et al., 2008).”
BackgroundOlzmann, J. A., Li, L., Chudaev, M. V., Chen, J., Perez, F. A., Palmiter, R. D., & Chin, L.-S. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200611128 · Cited by 339
“As we and others reported previously (Miller et al., 2003; Moore et al., 2003; Gorner et al., 2004; Olzmann et al., 2004), the steady-state level of L166P mutant DJ-1 was substantially lower compared with wild-type DJ-1.”
Mechanisms of mitophagy: PINK1, Parkin, USP30 and beyond
Bingol, B., & Sheng, M. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.04.015 · Cited by 334
Stavoe, A. K. H., & Holzbaur, E. L. F. (2019) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-100818-125242 · Cited by 328
“Knockout mice exhibit relatively subtle phenotypes, including altered synaptic excitability and decreased dopamine release, which do not clearly model human PD (Goldberg et al. 2003, Kitada et al. 2007, Perez & Palmiter 2005).”
BackgroundPickrell, A. M., Huang, C.-H., Kennedy, S. R., Ordureau, A., Sideris, D. P., Hoekstra, J. G., Harper, J. W., & Youle, R. J. (2015) · Neuron · doi:10.1016/j.neuron.2015.06.034 · Cited by 327
“Parkin-knockout (KO) mice do not show significant motor phenotypes, DA metabolism abnormalities, or signs of nigrostriatal degeneration (Goldberg et al., 2003; Kitada et al., 2009; Perez and Palmiter, 2005).”
InfluentialImpaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease
Büeler, H. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.03.006 · Cited by 327
“In mice, the same gene defects result in mitochondrial dysfunction and abnormalities in dopamine release (Palacino et al., 2004; Kitada et al., 2007; Gautier et al., 2008; Itier et al., 2003; Goldberg et al., 2003), suggesting that these are early abnormalities preceding dopamine neuron loss.”
BackgroundUnderstanding the molecular causes of Parkinson's disease
Wood-Kaczmar, A., Gandhi, S., & Wood, N. W. (2006) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.09.007 · Cited by 327
The Role of Innate and Adaptive Immunity in Parkinson's Disease
Kannarkat, G. T., Boss, J. M., & Tansey, M. G. (2013) · Journal of Parkinson’s Disease · doi:10.3233/jpd-130250 · Cited by 324
“Parkin knockout animals do not have loss of DA neurons in the SN and do not have increased vulnerability to MPTP, yet they do show non-motor behavioral changes related to changes in the nigrostriatal pathway [171, 172].”
BackgroundLampert, M. A., Orogo, A. M., Najor, R. H., Hammerling, B. C., Leon, L. J., Wang, B. J., Kim, T., Sussman, M. A., & Gustafsson, Å. B. (2019) · Autophagy · doi:10.1080/15548627.2019.1580095 · Cited by 313
“CPCs were isolated from ~2 month old homozygous polg, prkn [65], and wild-type mice as described previously [10].”
MethodThe Genetics of Parkinson Disease
Bekris, L. M., Mata, I. F., & Zabetian, C. P. (2010) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988710383572 · Cited by 301
R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice
Tong, Y., Pisani, A., Martella, G., Karouani, M., Yamaguchi, H., Pothos, E. N., & Shen, J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906334106 · Cited by 304
“Similar to our prior findings in parkin / (33), DJ-1 / (26, 34), and PINK1 / mice (35), the R1441C KI mouse does not develop nigrostriatal DA degeneration during its lifespan, providing further evidence that genetic recapitulation of pathogenic mutations in mice is insufficient to reproduce this terminal neuropatholog…”
Self-citationOxidative and nitrosative stress in Parkinson's disease
Tsang, A. H. K., & Chung, K. K. K. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.12.006 · Cited by 300
Alpha-synuclein and Protein Degradation Systems: a Reciprocal Relationship
Xilouri, M., Brekk, O. R., & Stefanis, L. (2013) · Molecular Neurobiology · doi:10.1007/s12035-012-8341-2 · Cited by 299
“The 26S proteasome comprises of two multimeric protein complexes, the 20S barrel-shaped core particle, where actual proteolysis occurs, and two 19S regulatory particles that regulate the function of the 20S [14–16].”
Synaptic Dysfunction in Parkinson’s Disease
Picconi, B., Piccoli, G., & Calabresi, P. (2012) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-7091-0932-8_24 · Cited by 290
“Furthermore the mice had a poor performance in terms of spontaneous activities and generalized hypokinesia in open field (Goldberg et al. 2003, 2005).”
Cell death pathways in Parkinson’s disease: proximal triggers, distal effectors, and final steps
Levy, O. A., Malagelada, C., & Greene, L. A. (2009) · Apoptosis · doi:10.1007/s10495-008-0309-3 · Cited by 287
“Both parkin [118, 119] and PINK1 [120, 121] knockout mice have reduced mitochondrial respiratory function with normal (or minimally changed) mitochondrial morphology and no signs of neurodegeneration (with the exception of one parkin-null line with mild neuronal loss in the locus ceruleus [122]).”
Dopamine release in the basal ganglia
Rice, M. E., Patel, J. C., & Cragg, S. J. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.08.066 · Cited by 282
“Interestingly, striatal [DA] o monitored in vivo using microdialysis are slightly elevated in parkin−/− mice (Goldberg et al., 2003), indicating that other processes, e.g., DA neuron activity, contribute to basal levels.”
BackgroundInfluentialKurihara, Y., Kanki, T., Aoki, Y., Hirota, Y., Saigusa, T., Uchiumi, T., & Kang, D. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.280156 · Cited by 279
Mitochondrial quality control in health and in Parkinson’s disease
Eldeeb, M. A., Thomas, R. A., Ragheb, M. A., Fallahi, A., & Fon, E. A. (2022) · Physiological Reviews · doi:10.1152/physrev.00041.2021 · Cited by 265
Mitophagy in Alzheimer’s Disease and Other Age-Related Neurodegenerative Diseases
Cai, Q., & Jeong, Y. Y. (2020) · Cells · doi:10.3390/cells9010150 · Cited by 265
Parkin Deficiency Increases Vulnerability to Inflammation-Related Nigral Degeneration
Frank-Cannon, T. C., Tran, T., Ruhn, K. A., Martinez, T. N., Hong, J., Marvin, M., Hartley, M., Treviño, I., O'Brien, D. E., Casey, B., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3001-08.2008 · Cited by 261
“Although parkin / mice have dopaminergic system dysfunction, unlike humans bearing parkin mutations, they do not display nigrostriatal pathway degeneration (Goldberg et al., 2003; Itier et al., 2003; Von Coelln et al., 2004; Zhu et al., 2007).”
BackgroundSelf-citationAbsence of nigral degeneration in aged parkin/DJ‐1/PINK1 triple knockout mice
Kitada, T., Tong, Y., Gautier, C. A., & Shen, J. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06350.x · Cited by 261
Self-citationThe ubiquitin–proteasome pathway in Parkinson's disease and other neurodegenerative diseases
Ross, C. A., & Pickart, C. M. (2004) · Trends in Cell Biology · doi:10.1016/j.tcb.2004.10.006 · Cited by 261
Age-dependent Motor Deficits and Dopaminergic Dysfunction in DJ-1 Null Mice
Chen, L., Cagniard, B., Mathews, T., Jones, S., Koh, H. C., Ding, Y., Carvey, P. M., Ling, Z., Kang, U. J., & Zhuang, X. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413955200 · Cited by 261
Ved, R., Saha, S., Westlund, B., Perier, C., Burnam, L., Sluder, A., Hoener, M., Rodrigues, C. M. P., Alfonso, A., Steer, C., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m505910200 · Cited by 255
Programming axonal mitochondrial maintenance and bioenergetics in neurodegeneration and regeneration
Cheng, X.-T., Huang, N., & Sheng, Z.-H. (2022) · Neuron · doi:10.1016/j.neuron.2022.03.015 · Cited by 251
Genetic clues to the pathogenesis of Parkinson's disease
Vila, M., & Przedborski, S. (2004) · Nature Medicine · doi:10.1038/nm1068 · Cited by 255
“Parkin-null mice and flies do not develop degeneration of nigrostriatal dopaminergic neuron”
BackgroundBehavioral models of Parkinson's disease in rodents: A new look at an old problem
Meredith, G. E., & Kang, U. J. (2006) · Movement Disorders · doi:10.1002/mds.21010 · Cited by 250
Molecular pathogenesis of Parkinson's disease
Gandhi, S., & Wood, N. W. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi308 · Cited by 251
“Despite these in vitro findings, modelling parkin associated PD in vivo has proved challenging: mice with targeted deletion of exon 3 of parkin do not show nigral neuronal loss (37).”
BackgroundEtiology of Parkinson’s disease
Schapira, A. H. V. (2006) · Neurology · doi:10.1212/wnl.66.10_suppl_4.s10 · Cited by 250
Drosophila Models of Neurodegenerative Diseases
Lu, B., & Vogel, H. (2009) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.3.121806.151529 · Cited by 248
Ko, H. S., von Coelln, R., Sriram, S. R., Kim, S. W., Chung, K. K. K., Pletnikova, O., Troncoso, J., Johnson, B., Saffary, R., Goh, E. L., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2172-05.2005 · Cited by 247
“…of parkin exon 3, which have subtle behavioral deficits and enhanced dopamine metabolism without loss of dopaminergic neurons (Goldberg et al., 2003; Itier et al., 2003), surprisingly, showed similar levels of CDCrel-1, synphilin-1, and ␣-synuclein (Goldberg et al., 2003; Palacino et al., 2004).”
BackgroundLewy body Parkinson's disease in a large pedigree with 77Parkin mutation carriers
Pramstaller, P. P., Schlossmacher, M. G., Jacques, T. S., Scaravilli, F., Eskelson, C., Pepivani, I., Hedrich, K., Adel, S., Gonzales-McNeal, M., Hilker, R., et al. (2005) · Annals of Neurology · doi:10.1002/ana.20587 · Cited by 247
“Notably, although the reported ubiquitin ligase activity of the Parkin gene product has been suggested in numerous studies, it has not yet been convincingly demonstrated in carefully examined mouse models of targeted parkin gene disruption.(39,40) Alternatively, an in-frame splicing event of mutant Parkin alleles (whi…”
BackgroundUbiquitin–proteasome system and Parkinson's diseases
Betarbet, R., Sherer, T. B., & Greenamyre, J. T. (2005) · Experimental Neurology · doi:10.1016/j.expneurol.2004.08.021 · Cited by 245
Unregulated Cytosolic Dopamine Causes Neurodegeneration Associated with Oxidative Stress in Mice
Chen, L., Ding, Y., Cagniard, B., Van Laar, A. D., Mortimer, A., Chi, W., Hastings, T. G., Kang, U. J., & Zhuang, X. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3602-07.2008 · Cited by 239
“Parkin-deficient mice have been reported to have increased extracellular dopamine (Bonifati et al., 2003; Goldberg et al., 2003).”
BackgroundPINK1-PRKN mediated mitophagy: differences between in vitro and in vivo models
Han, R., Liu, Y., Li, S., Li, X.-J., & Yang, W. (2023) · Autophagy · doi:10.1080/15548627.2022.2139080 · Cited by 229
Evolving and Expanding the Roles of Mitophagy as a Homeostatic and Pathogenic Process
Gustafsson, Å. B., & Dorn, G. W. (2019) · Physiological Reviews · doi:10.1152/physrev.00005.2018 · Cited by 228
Animal models of Parkinson’s disease progression
Meredith, G. E., Sonsalla, P. K., & Chesselet, M.-F. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0350-x · Cited by 228
“Two separate lines of mice with exon3 mutations leading to a lack of protein expression show progressive sensorimotor dysfunction without DA cell loss [44,57], whereas one line with an exon7 deletion showed anomalies in paired-pulse inhibition and a non-progressive loss of NE”
BackgroundSelf-citationEvaluation of Models of Parkinson's Disease
Jagmag, S. A., Tripathi, N., Shukla, S. D., Maiti, S., & Khurana, S. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00503 · Cited by 226
Sriram, S. R., Li, X., Ko, H. S., Chung, K. K. K., Wong, E., Lim, K. L., Dawson, V. L., & Dawson, T. M. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi292 · Cited by 223
Metadata
- Authors
- Goldberg, M. S., Fleming, S. M., Palacino, J. J., Cepeda, C., Lam, H. A., Bhatnagar, A., Meloni, E. G., Wu, N., Ackerson, L. C., Klapstein, G. J., Gajendiran, M., Roth, B. L., Chesselet, M.-F., Maidment, N. T., Levine, M. S., & Shen, J.
- Affiliations
- Brigham and Women's Hospital (US)
- University of California, Los Angeles (US)
- Case Western Reserve University (US)
- Corresponding author
- Shen, Jie
- ORCID
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2003-10
- Volume
- 278
- Issue
- 44
- Pages
- 43628-43635
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2088962120
- Cited by
- 913
- References
- 72
- Citations by year
- 2026: 8 · 2025: 25 · 2024: 35 · 2023: 27 · 2022: 45 · 2021: 39 · 2020: 39 · 2019: 25 · 2018: 39 · 2017: 40 · 2016: 29 · 2015: 34 · 2014: 41 · 2013: 43 · 2012: 36
- FWCI
- 33.13
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6206 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Keywords
- Parkin, Parkinson's disease, nigrostriatal pathway, dopaminergic neurons, substantia nigra, striatum, dopaminergic modulation, synaptic excitability, spiny neurons, E3 ubiquitin ligase, alpha-synuclein, synphilin-1, neuronal survival
- MeSH terms
- Alleles, Animals, Behavior, Animal, Brain, Chromatography, High Pressure Liquid, Disease Models, Animal, Dopamine, Electrophysiology, Mice, Transgenic, Models, Genetic, Neurons, Parkinson Disease, Receptors, Dopamine, Substantia Nigra, Time Factors, Blotting, Western, Germ-Line Mutation, Ubiquitin-Protein Ligases, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.